Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with multiple myeloma that has come back or stopped responding to treatment, and you are currently receiving a type of targeted therapy called a bispecific antibody (a specific kind of cancer drug)
- You have received at least 1 but no more than 4 rounds (cycles) of this bispecific antibody treatment
- You are 18 years old or older at the time you give your consent to join
- Your overall health and ability to carry out daily activities meets a certain minimum level (confirm with trial site)
- Doctors expect you to live for more than 12 months
Who may not be able to join:
- You had a stem cell transplant within the 3 months before joining the trial
- You are planning to receive a CAR-T cell therapy within the next 6 months
- You have had more than one serious deep-seated infection in the past 3 months
- You have HIV, or a currently active Hepatitis C or Hepatitis B infection
- You are currently pregnant
- Your blood counts for infection-fighting cells (neutrophils) or platelets are below certain minimum levels (confirm with trial site)
- You have had another type of cancer in the last 3 years that required active chemotherapy or radiation treatment
- You have a known allergy or reaction to IgG products, which are a type of antibody-based medicine
- You have had a bleed in the brain or a stroke caused by a blood clot in the last 6 months
- You have a condition where you have too much protein in your blood (hyperproteinemia)
- You have a condition where your body loses protein through your digestive system (protein-losing enteropathy)
- Your kidneys are not working well enough, based on a specific measurement of kidney function (confirm with trial site)
- Your multiple myeloma has been shown to be getting worse while on the bispecific antibody treatment
- You have a known history of a condition called hyperprolinemia, which means you have too much of a certain amino acid in your blood
- You are currently receiving, or have received in the last 3 months, a treatment called IVIG (a medicine made from donated blood proteins given through a drip)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zainab Shahid, MBBS, Memorial Sloan Kettering Cancer Center
Phone: 212-639-6483
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Difference in overall infection rates between Standard of Care participants and participants receiving IgPro20
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.